[Atorvastatin for primary prevention of cardiovascular events. ASCOT-LLA Study].
März
W
W
Klinisches Institut für Medizinische und Chemische Labordiagnostik, LKH und Universitätsklinikum Graz, Osterreich. winfried.maerz@klinikum-graz.at
D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000069059:Atorvastatin; D002318:Cardiovascular Diseases / Q000097:blood / Q000401:mortality / Q000517:prevention & control*; D002423:Cause of Death; D002784:Cholesterol / Q000097:blood; D005260:Female; D006538:Heptanoic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D011758:Pyrroles; D002784:Cholesterol; D000069059:Atorvastatin